CLDI - Calidi Biotherapeutics, Inc.

0.426
-0.070   -16.455%

Share volume: 679,484
Last Updated: 04-08-2025
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: -0.07%

PREVIOUS CLOSE
CHG
CHG%
$0.50
-0.07
-0.14%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
3%
Profitability 0%
Dept financing 25%
Liquidity 4%
Performance 0%
Company vs Stock growth
vs
N/A
1.650 2.110
0.460 27.88%
+ Add row to compare
Performance
5 Days
-14.13%
1 Month
-46.10%
3 Months
-53.44%
6 Months
-57.82%
1 Year
-30.97%
2 Year
-99.59%
Key data
Stock price
$0.43
P/E Ratio 
0.00
DAY RANGE
$0.40 - $0.55
EPS 
-$17.25
52 WEEK RANGE
$0.14 - $3.89
52 WEEK CHANGE
-$27.45
MARKET CAP 
9.216 M
YIELD 
N/A
SHARES OUTSTANDING 
8.084 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
04-15-2025
BETA 
0.94
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$508,690
AVERAGE 30 VOLUME 
$415,834
Company detail
CEO: Allan J. Camaisa
Region: US
Website: www.calidibio.com
Employees: 38
IPO year: 2021
Issue type: Common Stock
Market: NYSE American
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing immunotherapies for the treatment of cancer. The company was founded in 2014 and is based in San Diego, California.

Recent news
loading